Biogazelle and Isis evaluate long non-coding RNAs to identify and validate novel targets for anti-cancer drugs

October 15, 2015 Leave a comment 2,703 Views

GHENT, Belgium, October 15, 2015 – Biogazelle NV today announced a research-stage collaboration with Isis Pharmaceuticals in which they will identify and validate novel targets to treat colon, liver and lung cancer, diseases with clear unmet clinical needs. As part ...

RNA-Seq Blog Transcriptome Research & Industry News

Tag Archives: Isis Pharmaceuticals

Biogazelle and Isis evaluate long non-coding RNAs to identify and validate novel targets for anti-cancer drugs

Complete Guide to Understanding Single-Cell RNA-Seq

cFIT – integration and transfer learning of single-cell transcriptomes

Learn more about available bioinformatics tools and pipelines to analyze RNA sequencing data

New search engine for single cell atlases

Yale researchers identify tumor reactive immune cells with RNA sequencing to help fight against advanced melanoma

New algorithm identifies ‘escaping’ cells in single-cell CRISPR screens

RNA sequencing brings hope for endangered wild cats